Table 3:

Association between prescription of specific antiretroviral drugs and fasting plasma glucose monitoring rates

				Univariate#			Multivariate~
	Person-years	Assessments (n)	Crude rate	IRR	95%CI	P-value	IRR	95%CI	P-value
ZDV
No	30526.5	14186	0.46	1.00			1.00
Yes	32090.6	12584	0.39	1.05	1.02–1.08	0.002	1.02	0.99–1.05	0.191
d4T
No	39671.5	19939	0.50	1.00			1.00
Yes	22945.6	6831	0.30	1.05	1.02–1.09	0.004	1.01	0.97–1.04	0.671
ddI
No	59955.7	24146	0.40	1.00			1.00
Yes	2661.5	2624	0.99	1.10	1.04–1.17	0.001	1.05	1.00–1.11	0.065
IDV
No	60939.5	24887	0.41	1.00			1.00
Yes	1677.6	1883	1.12	1.07	1.00–1.15	0.036	0.99	0.93–1.06	0.842
LPV
No	56315.9	20853	0.37	1.00			1.00
Yes	6301.2	5917	0.94	1.46	1.40–1.53	<0.001	1.43	1.37–1.49	<0.001

^#adjusted for site and year.

^~additionally adjusted for all factors significant in multivariable model (Table 2), i.e. sex, age HIV exposure category, CD4 count.

Use of specific antiretroviral drugs was time updated, as such, i.e. patient can contribute to more than one category.

IRR, incidence rate ratio; CI, confidence interval; ZDV, zidovudine; d4T, stavudine; ddI, didanosine; IDV, indinavir; LPV, lopinavir